RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy MK-1045 enters first human trial for Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests MK-1045, an immunotherapy that helps the immune system fight cancer, in 100 adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer that has returned or stopped responding to treatment). The main goals are to check safet…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New CAR t-cell therapy offers hope for children with hard-to-treat blood cancers
Disease control Recruiting nowThis study tests a new treatment called obe-cel for children whose B-cell leukemia or lymphoma has come back or not responded to standard therapy. Obe-cel uses the child's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is to se…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug hope for Tough-to-Treat lymphomas
Disease control Recruiting nowThis study tests a drug called pemigatinib in adults with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The main goal is to see if the drug can shrink tumors. About 27 people will take part, and the study is cu…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for tough lymphoma: first human trial of YK012 begins
Disease control Recruiting nowThis early-stage study tests a new drug called YK012 in 48 adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants will receive YK…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated May 14, 2026 12:03 UTC